GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IMGT Corp Ltd (XKRX:456570) » Definitions » Interest Expense

IMGT (XKRX:456570) Interest Expense : ₩-2,321.03 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is IMGT Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. IMGT's interest expense for the six months ended in Dec. 2023 was ₩ -2,321.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-2,321.03 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. IMGT's Operating Income for the six months ended in Dec. 2023 was ₩ -6,683.25 Mil. IMGT's Interest Expense for the six months ended in Dec. 2023 was ₩ -2,321.03 Mil. IMGT did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


IMGT Interest Expense Historical Data

The historical data trend for IMGT's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMGT Interest Expense Chart

IMGT Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Interest Expense
-686.96 -1,046.10 -2,001.34 -2,321.03

IMGT Semi-Annual Data
Dec20 Dec21 Dec22 Dec23
Interest Expense -686.96 -1,046.10 -2,001.34 -2,321.03

IMGT Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-2,321.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IMGT  (XKRX:456570) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

IMGT's Interest Expense for the six months ended in Dec. 2023 was ₩-2,321.03 Mil. Its Operating Income for the six months ended in Dec. 2023 was ₩-6,683.25 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was ₩68.75 Mil.

IMGT's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

IMGT did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


IMGT (XKRX:456570) Business Description

Traded in Other Exchanges
N/A
Address
172 Dolma-ro,, 408, Healthcare Innovation Park, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13605
IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.

IMGT (XKRX:456570) Headlines

No Headlines